PIRAZOLOPIRAMIDINON JEDINJENJE I POSTUPAK ZA NJEGOVO DOBIJANJE, opisana su pirazolopirimidinon antianginalna sredstva, jedinjenja formule: i njihove farmaceutski prihvatljive soli, u kojoj: R1 je H; C1-C3 alkil opciono supstituisan sa jednim ili više fluoro supstituenata; ili C3-C5 cikloalkil; R2 je H, ili C1-C6 alkil opciono supstituisan sa jednim ili više fluoro supstituenata ili sa C3-C6 cikloalkil grupom; R3 je C1-C6 alkil opciono supstituisan sa jednim ili više fluoro supstituenata ili sa C3-C6 cikloalkil grupom; C3-C5 cikloalkil; C3-C6 alkenil; ili C3-C6 alkinil; R4 je C1-C4 alkil opciono supstituisan sa OH, NR5R6, CN, CONR5R6 ili CO2R7; C2-C4 alkenil opciono supstituisan sa CN, CONR5R6 ili CO2R7; C2-C4 alkanoil opciono supstituisan sa NR5R6; hidroksi C2-C4 alkil opciono supstituisan sa NR5R6; (C2-C3 alkoksi)C1-C2 alkil op-ciono supstituisan sa OH ili NR5R6; CONR5R6; CO2R7; halo; NR5R6; NHSO2-R8; ili fanil ili heterocikl svaki je opciono supstituisan sa motil grupom; R5 i R6 su svaki nezavisno H ili C1-C3 alkil, ili zajedno sa atomom azota za koji su vezani obrazuju pirolidinil, piperidino, morfolino, 4-(NR9)piperazinil ili imidazolil grupu pri čemu pomenuta grupa je opciono supstituisana sa metil ili hidroksi grupom; R7 je H ili C1-C4 alkil; R8 je C1-C3 alkil opciono supstituisan sa NR5R6; i R9 je H; C1-C3 alkil opciono supstituisan sa fenil grupom; hidroksi C2-C3 alkil; ili C1-C4 alkanoil; koja su selektivni cGMP PDE inhibitori korisni za tretiranje kardiovaskularnih oštećenja kao što su angina, hipertenzija, srčani nedostatak i ateroskleroza.Pyrazolopyramidinone Compound and Process for Obtaining It, Pyrazolopyrimidinone antianginal agents, compounds of formula: and their pharmaceutically acceptable salts, in which: R 1 is H; C1-C3 alkyl optionally substituted by one or more fluoro substituents; or C3-C5 cycloalkyl; R2 is H, or C1-C6 alkyl optionally substituted by one or more fluoro substituents or by a C3-C6 cycloalkyl group; R3 is C1-C6 alkyl optionally substituted by one or more fluoro substituents or by a C3-C6 cycloalkyl group; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R4 is C1-C4 alkyl optionally substituted by OH, NR5R6, CN, CONR5R6 or CO2R7; C2-C4 alkenyl optionally substituted by CN, CONR5R6 or CO2R7; C2-C4 alkanoyl optionally substituted with NR5R6; hydroxy C2-C4 alkyl optionally substituted with NR5R6; (C2-C3 alkoxy) C1-C2 alkyl optionally substituted by OH or NR5R6; CONR5R6; CO2R7; halo; NR5R6; NHSO2-R8; or a fanil or heterocycle are each optionally substituted by a motyl group; R 5 and R 6 are each independently H or C 1 -C 3 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4- (NR 9) piperazinyl or imidazolyl group wherein said group is optionally substituted by a methyl or hydroxy group ; R7 is H or C1-C4 alkyl; R8 is C1-C3 alkyl optionally substituted with NR5R6; and R 9 is H; C1-C3 alkyl optionally substituted by a phenyl group; hydroxy C2-C3 alkyl; or C1-C4 alkanoyl; which are selective cGMP PDE inhibitors useful for treating cardiovascular damage such as angina, hypertension, heart failure and atherosclerosis.